MTSR
Price performance
Nov 14, 2025Company activity
16 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 11/13/25 | MTSR | 8-K | Pfizer Completes Acquisition of Metsera, Inc. | — | — | — |
| 11/10/25 | MTSR | 8-K | Metsera, Inc. Amends Merger Agreement with Pfizer Inc. | — | — | — |
| 11/05/25 | MTSR | 8-K | Metsera Responds to Pfizer Litigation Ruling | — | — | — |
| 11/04/25 | MTSR | 8-K | Metsera Declares Novo Nordisk Proposal as Superior Company Proposal | — | — | — |
| 11/03/25 | MTSR | 8-K | Metsera Responds to Pfizer Litigation Amid Acquisition Proposal | — | — | — |
| 10/31/25 | MTSR | 8-K | Metsera, Inc. Responds to Pfizer Litigation and Announces Proposed Acquisition | — | — | — |
| 10/30/25 | MTSR | 8-K | Metsera Declares Novo Nordisk Proposal as Superior Company Proposal | — | — | — |
| 09/29/25 | MTSR | 8-K | Metsera Announces Positive Phase 2b Results for MET-097i | — | — | — |
| 09/22/25 | MTSR | 8-K | Pfizer Announces Acquisition of Metsera, Inc. | — | — | — |
| 07/28/25 | MTSR | 8-K | Metsera Reports Second Quarter 2025 Financial Results and Pipeline Update | — | — | — |
| 06/09/25 | MTSR | 8-K | Metsera Announces Topline Results from Phase 1 Trial of MET-233i | — | — | — |
| 05/12/25 | MTSR | 8-K | Metsera Reports Q1 2025 Financial Results and Pipeline Progress | — | — | — |
| 04/28/25 | MTSR | 8-K | Metsera Appoints New Board Member and Chief Legal Officer | — | — | — |
| 03/26/25 | MTSR | 8-K | Metsera, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Completed IPO | — | — | — |
| 03/10/25 | MTSR | 8-K | Metsera, Inc. Approves 2024 Annual Cash Bonuses for Executives | — | — | — |
| 02/03/25 | MTSR | 8-K | Metsera, Inc. Files Amended and Restated Certificate of Incorporation and Bylaws | — | — | — |
MTSR filing record
MTSR (MTSR): 16 8-K filings summarized, the most recent on Nov 13, 2025.
What the 8-K filings said
- Nov 13, 2025 · high impact
On November 13, 2025, Pfizer Inc. completed its acquisition of Metsera, Inc. through a merger. As a result, Metsera, Inc.'s common stock ceased trading on Nasdaq and was delisted. The board of directors of Metsera, Inc. resigned, and new directors from Pfizer's subsidiary were appointed. Additionally, Pfizer issued…
Pfizer Completes Acquisition of Metsera, Inc. - Nov 10, 2025 · high impact
On November 7, 2025, Metsera, Inc. announced an amendment to its previously disclosed merger agreement with Pfizer Inc. The amendment increases the upfront cash consideration from $47.50 to $65.60 per share and adjusts the contingent value rights (CVR) from up to $22.50 to up to $20.65 per share. The amendment also…
Metsera, Inc. Amends Merger Agreement with Pfizer Inc. - Nov 5, 2025 · high impact
On November 5, 2025, Metsera, Inc. issued a statement in response to a ruling in the litigation filed against the Company by Pfizer Inc. The Delaware Court of Chancery denied Pfizer's request for a temporary restraining order, allowing Metsera's Board of Directors to act in the best interests of shareholders. Metsera…
Metsera Responds to Pfizer Litigation Ruling - Nov 4, 2025 · low impact
On November 4, 2025, Metsera, Inc. announced that its Board of Directors determined that a revised proposal from Novo Nordisk A/S to acquire Metsera constitutes a 'Superior Company Proposal' under its existing Merger Agreement with Pfizer Inc. Novo Nordisk's proposal, which values Metsera at up to $86.20 per share…
Metsera Declares Novo Nordisk Proposal as Superior Company Proposal - Nov 3, 2025 · medium impact
On November 3, 2025, Metsera, Inc. issued a statement in response to litigation filed by Pfizer Inc., asserting that Pfizer is attempting to lower the acquisition price through litigation. Metsera's Board of Directors is committed to standing firm on behalf of shareholders. The litigation could impact the proposed…
Metsera Responds to Pfizer Litigation Amid Acquisition Proposal
SEC filings in the last five years
- 16 Form 8-K
- 3 Form 10-Q
- 1 Form 10-K